Minerva Neurosciences Stock Forecast
NASDAQ: NERVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 3.22 0.00%
NERV analyst consensus
Consensus (3 analysts)
none
Avg. price target
$10.33+220.81%
- Strong buy 1
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Minerva Neurosciences (2026-10-08), 2 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $10.33, with a high estimate of $14.00 and a low estimate of $7.00. The average target implies upside of 220.8% from the current price of $3.22.
The spread between the highest and lowest targets is 100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NERV.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 33% |
| Buy | 1 | 33% |
| Hold | 1 | 33% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | +117.39% |
| Average target | $10.33 | +220.81% |
| High target | $14.00 | +334.78% |